Indications for Pembrolizumab

Pembrolizumab has a wide range of indications and has been used to treat a variety of cancers after being approved by the U.S. Food and Drug Administration (FDA). It is currently administered through intravenous infusion. This drug is a prescription drug and can be used alone or in combination, but it must be carried out according to the doctor's prescription information and under the supervision of the doctor.

Pembrolizumab is approved for the treatment of unresectable or metastatic melanoma and adjuvant therapy after complete resection, non-small cell lung cancer (NSCLC) treated with combination or single agent, head and neck squamous cell carcinoma (HNSCC) treated with combination or single agent, Hodgkin lymphoma (cHL) that is relapsed or refractory or relapsed after multiple courses of treatment, and primary mediastinal large B-cell lymphoma (P MBCL), urothelial cancer with combination or single agent, microsatellite instability-high or mismatch repair deficient colorectal cancer (CRC), gastric cancer, esophageal cancer, cervical cancer with combination or single agent, hepatocellular carcinoma (HCC), Merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial cancer, tumor mutation load-high cancer, cutaneous squamous cell carcinoma (cSCC), triple negative breast cancer (TNBC).

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.